

VALNEVA SE

ISIN: FR0004056851

WKN: -

Overview

2024/07/16 08:21:20

Price

3.382 EUR

Difference



-0.29% (-0.01)

General attributes

ISIN FR0004056851

Symbol VLA

Exchange Hamburg

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 959 EUR

Benchmark CAC 40 INDEX

Market data

Bid (Bid size) -

Ask (Ask size) -

Open 3.382 EUR

High 3.382 EUR

Low 3.382 EUR

Close (prev. day) 3.392 EUR

VWAP -

Volume (pcs) 0

Trading volume 0.00

Number of trades 1

Last size 0

Futures and Options

Related Futures -

Related Options -

PDF Downloads

Company report: VALNEVA SE



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

Recent research

| on sector | | on market | |
|------------|--|-----------------------|----------|
| Date | | Headline | Download |
| 2024/07/12 | | Global Equity Ratings | |
| 2024/06/21 | | Global Equity Ratings | |
| 2024/06/14 | | Global Equity Ratings | |
| 2024/05/29 | | Global Equity Ratings | |
| 2024/04/26 | | Global Equity Ratings | |

Details

2024/07/16 08:21:20

Price

3.382 EUR

Difference ▼ -0.29% (-0.01)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | FR0004056851 |
| Symbol | VLA |
| Exchange | Hamburg |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 959 EUR |
| Benchmark | CAC 40 INDEX |

Market data

| | |
|-------------------|-----------|
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 3.382 EUR |
| High | 3.382 EUR |
| Low | 3.382 EUR |
| Close (prev. day) | 3.392 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|------|
| Perf (%) | -24.07% | -50.13% | - |
| Perf (abs.) | -1.08 | -3.41 | - |
| Beta | 1.42 | 1.30 | 1.06 |
| Volatility | 55.23 | 50.77 | - |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 3.336 EUR (920) |
| Ø price 30 days Ø volume 30 days (pcs.) | 3.454 EUR (695) |
| Ø price 100 days Ø volume 100 days (pcs.) | 3.549 EUR (472) |
| Ø price 250 days Ø volume 250 days (pcs.) | 4.632 EUR (358) |
| YTD High date | 4.909 EUR (2024/01/09) |
| YTD Low date | 3.020 EUR (2024/03/05) |
| 52 Weeks High date | 7.146 EUR (2023/11/10) |
| 52 Weeks Low date | 3.020 EUR (2024/03/05) |

All listings for VALNEVA SE

| Exchange ⊕ | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-------------------------|------------|-------|-----------|-----------------------|------------------|
| Xetra | 2024/07/16 | 17:35 | 3.46 EUR | 0.04 | 28 |
| Vienna Stock Exchange | 2024/07/16 | 15:30 | 3.434 EUR | 0.00 | 4 |
| Tradegate | 2024/07/16 | 22:02 | 3.458 EUR | 0.16 | 69 |
| Stuttgart | 2024/07/16 | 16:52 | 3.542 EUR | 0.02 | 8 |
| Munich | 2024/ | 19:33 | 3.494 EUR | 0.01 | 4 |

| | | | | | | |
|---|----------------|-------|-----------|------|--|-----|
| | 07/16 | | | | | |
| London Stock Exchange | 2024/ 05/02 | 17:57 | 3.40 EUR | 0.03 | | 1 |
| Hanover | 2024/ 07/16 | 08:48 | 3.396 EUR | 0.00 | | 1 |
| Hamburg | 2024/ 07/16 | 08:21 | 3.382 EUR | 0.00 | | 1 |
| Frankfurt | 2024/ 07/16 | 19:13 | 3.484 EUR | 0.02 | | 7 |
| FINRA other OTC Issues | 2024/ 07/12 | 16:44 | 3.70 USD | 0.00 | | 1 |
| Euronext Paris | 2024/ 07/16 | 17:35 | 3.494 EUR | 1.48 | | 813 |
| Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | | - |
| Duesseldorf | 2024/ 07/16 | 20:02 | 3.488 EUR | 0.00 | | 6 |
| Berlin | 2024/ 07/16 | 08:08 | 3.372 EUR | 0.00 | | 1 |

Company profile

Company Logo



Contact Details

VALNEVA SE

--

Campus Bio-Ouest, 6, rue Alain Bombard -
44800 Saint-Herblain

Telefon: +33-2-28-07-37-10

Fax: +

E-mail: info@valneva.com

PDF Downloads

Company report: VALNEVA SE



Company Profile

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Thomas Lingelbach | Chairman of Managing Board |
| Dipal Patel | Member of Executive Committee |
| Franck Grimaud | Member of Executive Committee |
| Frederic Jacotot | Member of Executive Committee |
| Juan Carlos Jaramillo | Member of Executive Committee |
| Peter Bühler | Member of Executive Committee |
| Petra Pesendorfer | Member of Executive Committee |
| Vincent Dequenne | Member of Executive Committee |

Board of directors

| | |
|------------------------|-------------------------------|
| Anne-Marie Graffin | Chairman of Supervisory Board |
| Kathrin Jansen | Member of Supervisory Board |
| Danièle Guyot-Caparros | Member of Supervisory Board |
| James Connolly | Member of Supervisory Board |
| James Sulat | Member of Supervisory Board |
| Maillys Ferrère | Member of Supervisory Board |